Payment overview · 2025
General Payments
$521.39
24 reported records · 6 companies
Healthcare provider profile · identity verified
Jonathan H Fuller, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GADSDEN, AL · NPI 1013315001
Verified facts
What the public records show
CMS Open Payments records show Jonathan H Fuller, D.O. received $521.39 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 52.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 383 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.98 | 52.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.22 | 18.3% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.16 | 12.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.77 | 8.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.94 | 6.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.32 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $521.39 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $163.93 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $105.44 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $94.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.90 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.90 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.16 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.16 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.77 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 383 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
150 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
339 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
383 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
174 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1335 | 414 |
| Lisinopril | Lisinopril | 703 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 673 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 592 | 164 |
| Omeprazole | Omeprazole | 538 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 532 | 166 |
| Gabapentin | Gabapentin | 513 | 122 |
| Losartan Potassium | Losartan Potassium | 513 | 165 |
| Metformin Hcl | Metformin Hcl | 503 | 155 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 412 | 146 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 384 | 113 |
| Ozempic | Semaglutide | 383 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 344 | 115 |
| Mounjaro | Tirzepatide | 339 | 55 |
| Sertraline Hcl | Sertraline Hcl | 329 | 97 |
| Montelukast Sodium | Montelukast Sodium | 322 | 107 |
| Simvastatin | Simvastatin | 289 | 74 |
| Trazodone Hcl | Trazodone Hcl | 288 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 70 |
| Carvedilol | Carvedilol | 281 | 96 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 258 | 199 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 257 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 77 |
| Alprazolam | Alprazolam | 225 | 44 |
| Alendronate Sodium | Alendronate Sodium | 220 | 77 |
| Prednisone | Prednisone | 210 | 130 |
| Pregabalin | Pregabalin | 201 | 51 |
| Potassium Chloride | Potassium Chloride | 196 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 195 | 46 |
| Methylprednisolone | Methylprednisolone | 193 | 156 |
| Tramadol Hcl | Tramadol Hcl | 186 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 175 | 58 |
| Famotidine | Famotidine | 175 | 59 |
| Eliquis | Apixaban | 174 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 162 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 161 | 52 |
| Meloxicam | Meloxicam | 160 | 56 |
| Furosemide | Furosemide | 152 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 150 | 58 |
| Ibuprofen | Ibuprofen | 149 | 90 |
| Glipizide Er | Glipizide | 146 | 43 |
| Clonazepam | Clonazepam | 139 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 42 |
| Fenofibrate | Fenofibrate | 127 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 35 |
| Metformin Hcl Er | Metformin Hcl | 121 | 39 |
| Temazepam | Temazepam | 119 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 110 | 77 |
| Celecoxib | Celecoxib | 105 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 104 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 31 |
| Topiramate | Topiramate | 102 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 55 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 36 |
| Allopurinol | Allopurinol | 98 | 35 |
| Jardiance | Empagliflozin | 98 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 75 |
| Meclizine Hcl | Meclizine Hcl | 95 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 26 |
| Xarelto | Rivaroxaban | 94 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 90 | 70 |
| Levofloxacin | Levofloxacin | 89 | 67 |
| Diazepam | Diazepam | 85 | 18 |
| Donepezil Hcl | Donepezil Hcl | 85 | 26 |
| Ezetimibe | Ezetimibe | 80 | 27 |
| Januvia | Sitagliptin Phosphate | 79 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 32 |
| Methocarbamol | Methocarbamol | 76 | 46 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 21 |
| Atenolol | Atenolol | 73 | 22 |
| Promethazine Hcl | Promethazine Hcl | 73 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 24 |
| Spironolactone | Spironolactone | 72 | 25 |
| Trulicity | Dulaglutide | 72 | 19 |
| Buspirone Hcl | Buspirone Hcl | 69 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 13 |
| Myrbetriq | Mirabegron | 68 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 19 |
| Glimepiride | Glimepiride | 62 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 38 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 21 |
| Lorazepam | Lorazepam | 60 | 15 |
| Clonidine Hcl | Clonidine Hcl | 59 | 23 |
| Bupropion Xl | Bupropion Hcl | 58 | 21 |
| Linzess | Linaclotide | 58 | 19 |
| Mirtazapine | Mirtazapine | 58 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 52 |
| Fluconazole | Fluconazole | 57 | 36 |
| Valacyclovir | Valacyclovir Hcl | 56 | 33 |
| Farxiga | Dapagliflozin Propanediol | 55 | 19 |
| Finasteride | Finasteride | 55 | 12 |
| Memantine Hcl | Memantine Hcl | 55 | 17 |
| Nystatin | Nystatin | 55 | 33 |
| Estradiol | Estradiol | 54 | 21 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 17 |
| Glipizide | Glipizide | 50 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 14 |
| Vascepa | Icosapent Ethyl | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 16 |
| Primidone | Primidone | 43 | 16 |
| Sucralfate | Sucralfate | 43 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Lovastatin | Lovastatin | 40 | 13 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 11 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 33 | 19 |
| Entresto | Sacubitril/Valsartan | 32 | 11 |
| Baclofen | Baclofen | 31 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Dilt-Xr | Diltiazem Hcl | 28 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Lactulose | Lactulose | 18 | 14 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $521.39 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, JARDIANCE, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, WAINUA, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error